Alzheimer’s treatment by transporting antibodies across the blood–brain barrier

#lifesciences #neurodegenerativediseases #alzheimerdisease #antibodies #bloodbrainbarrier #drugdevelopment #drugdesign Researchers from Japan have found a way to ensure that new medications are delivered to the right place in the body and at the right timepoint in disease progression, so that they have the best effect. In a recent study, researchers led by Tokyo Medical and Dental University (TMDU) have revealed that a novel delivery system delivers treatment to where it is needed most in a mouse model of Alzheimer’s disease (AD). AD is a common neurodegenerative disease that causes dementia. It is characterized by the accumulation of a protein called amyloid β (Aβ) in the brain, and a number of different toxic forms of Aβ have been identified that impair brain function, notably Aβ oligomers (AβOs). To address this challenge, the researchers previously developed glucosylated (sugar-linked) polymeric nanomicelles (PMs), which are tiny, hollow balls that could successfully cross the BBB via transcytosis in mouse brain capillary endothelial cells; this process was mediated by glucose-transporter-1 and induced by an increase in blood glucose levels after the mice experienced fasting conditions. In this study, the team filled PMs with fragments of an anti-AβO antibody, injected them into a mouse model of AD, and assessed the effects on the brain and on behavior. Get the latest medical and health news at medicaldialogues.in Follow us on Twitter:   / medicaldialogs   Facebook:   / medicaldialogues   Instagram:   / medicaldialogues   LinkedIn:   / medical-dialogues   Website: https://medicaldialogues.in/